水蛭素活性因子抗癌作用的实验研究

Experimental study of anti-tumor effect of hirudin active factor

目的观察水蛭素活性因子对H22肝癌瘤细胞、S180肉瘤的抑制作用,为临床用药提供理论依据。方法取小鼠48只,每只小鼠左前腋下接种H22肝癌瘤细胞0.2 mL,随机分为4组,每组12只,分成模型对照组、5-FU组、水蛭素活性因子大剂量组(水蛭素活性因子2.6 g/kg)和水蛭素活性因子小剂量组(水蛭素活性因子1.3 g/kg);另取小鼠44只,每只小鼠左前腋下接种S180肉瘤细胞0.2 mL,随机分为4组,每组11只,分成模型对照组、5-FU组、水蛭素活性因子大剂量组(水蛭素活性因子2.6 g/kg)和水蛭素活性因子小剂量组(水蛭素活性因子1.3 g/kg);连续给药14 d,比较各组肿瘤生长情况,并计算抑瘤率。结果①水蛭素活性因子对H22肝癌实体瘤的影响:5-FU组[瘤重(0.78±0.41)g]、水蛭素活性因子大剂量组[瘤重(0.99±0.48)g]、水蛭素活性因子小剂量组[瘤重(1.15±0.50)g]对H22肝癌抑瘤率分别为58.73%、47.62%、39.15%,与模型对照组相比,差异均有统计学意义(P<0.05或P<0.01),其中水蛭素活性因子大、小剂量组比较,大剂量组抑瘤作用明显优于小剂量组(P<0.05),呈现一定的量效关系。②水蛭素活性因子对S180肉瘤的影响:5-FU组[瘤重(0.68±0.30)g]、水蛭素活性因子大剂量组[瘤重(0.85±0.44)g]、水蛭素活性因子小剂量组[瘤重(0.89±0.47)g]对S180肉瘤抑瘤率分别为54.67%、43.33%、40.67%,与模型对照组相比,差异均有统计学意义(P<0.05或P<0.01),其中水蛭素活性因子大、小剂量组比较,差异无统计学意义(P>0.05)。③所有5-FU组小鼠在给药第9天开始出现精神萎靡、蜷缩少动、脱毛、食欲减退等,而水蛭素活性因子组小鼠未发生此现象。结论水蛭素活性因子对H22肝癌瘤细胞和S180肉瘤均有较好的抑制作用,且水蛭素因子无明显副作用。

Objective To observe the anti-tumor effect of hirudin active factor on H22 liver tumor cells and S180 sarcoma,thus to provide theoretical basis for clinical pharmacy.Methods 48 mice were selected,0.2 mL H22 liver tumor cells inoculated subcutaneously,divided into 4 groups,each group had 12 mice.Four groups were named as control group,5-FU group,high-dose hirudin group （hirudin active factor 2.6 g/kg）,low-dose hirudin group （hirudin active factor 1.3 g/kg）.Another 44 mice were selected,0.2 mL S180 sarcoma cell inoculated subcutaneously,divided into 4 groups,each group had 11 mice.Four groups were named as control group,5-FU group,high-dose hirudin group （hirudin active factor 2.6 g/kg）,low-dose hirudin group （hirudin active factor 1.3 g/kg）.All mice were treated by saline,5-FU group,high-dose hirudin,low-dose hirudin respectively for 14 days daily.The growth of carcinoma cell were compared,and the anti-carcinoma rate was calculated.Results ①The effect of hirudin active factor on H22 solid liver cancer：the anti-carcinoma rates of 5-FU group [tumor weight （0.78±0.41） g],high-dose hirudin group [tumor weight （0.99±0.48） g],low-dose hirudin group [tumor weight （1.15±0.50） g] to H22 solid liver cancer were 58.73%,47.62% and 39.15% respectively,had obvious difference compared to control group （P 〈 0.01 or P 〈 0.05）; and the anti-carcinoma rate of high-dose hirudin group was obviously higher than the low-dose hirudin group （P 〈 0.05）,which showed dose-effect relationship.②The effect of hirudin active factor on S180 sarcoma cell：the anti-carcinoma rates of 5-FU group [tumor weight （0.68±0.30） g],high-dose hirudin group [tumor weight （0.85±0.44）g],low-dose hirudin group [tumor weight （0.89±0.47） g] to S180 sarcoma cell were 54.67%,43.33% and 40.67% respectively,had obvious difference compared to control group （P 〈 0.01 or P 〈 0.05）; and the difference of anti-carcinoma rate was not obvious between high-dose hirudin group and low-dose hirudin group （P 〉 0.05）.③All the mice of 5-FU group got malaise,curled up,hair slip and eat less on day 9,the mice of hirudin active factor group were escapable of those phenomena.Conclusion Hirudin active factor can restrain the growth of H22 liver tumor cells and S180 sarcoma obviously,and which has no side effect.